Literature DB >> 21691740

Insights on PRAME and osteosarcoma by means of gene expression profiling.

Sílvia Regina Caminada Toledo1, Marco Antonio Zago, Indhira Dias Oliveira, Rodrigo Proto-Siqueira, Oswaldo K Okamoto, Patricia Severino, Ricardo Z N Vêncio, Francine Tesser Gamba, Wilson A Silva, Carlos A Moreira-Filho, Cristiane A Dalla Torre, Maria Tereza Seixas Alves, Reynaldo J Garcia-Filho, Andrew J G Simpson, Antonio Sergio Petrilli.   

Abstract

BACKGROUND: Osteosarcoma (OS) is the most frequent bone tumor in children and adolescents. Tumor antigens are encoded by genes that are expressed in many types of solid tumors but are silent in normal tissues, with the exception of placenta and male germ-line cells. It has been proposed that antigen tumors are potential tumor markers.
OBJECTIVES: The premise of this study is that the identification of novel OS-associated transcripts will lead to a better understanding of the events involved in OS pathogenesis and biology.
METHODS: We analyzed the expression of a panel of seven tumor antigens in OS samples to identify possible tumor markers. After selecting the tumor antigen expressed in most samples of the panel, gene expression profiling was used to identify osteosarcoma-associated molecular alterations. A microarray was employed because of its ability to accurately produce comprehensive expression profiles.
RESULTS: PRAME was identified as the tumor antigen expressed in most OS samples; it was detected in 68% of the cases. Microarray results showed differences in expression for genes functioning in cell signaling and adhesion as well as extracellular matrix-related genes, implying that such tumors could indeed differ in regard to distinct patterns of tumorigenesis.
CONCLUSIONS: The hypothesis inferred in this study was gathered mostly from available data concerning other kinds of tumors. There is circumstantial evidence that PRAME expression might be related to distinct patterns of tumorigenesis. Further investigation is needed to validate the differential expression of genes belonging to tumorigenesis-related pathways in PRAME-positive and PRAME-negative tumors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21691740     DOI: 10.1007/s00776-011-0106-7

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  6 in total

1.  Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.

Authors:  Nicolas J Llosa; Kenneth R Cooke; Allen R Chen; Christopher J Gamper; Orly R Klein; Elias T Zambidis; Brandon Luber; Gary Rosner; Nicholas Siegel; Mary Jo Holuba; Nancy Robey; Masanori Hayashi; Richard J Jones; Ephraim Fuchs; Matthias Holdhoff; David M Loeb; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-12       Impact factor: 5.742

2.  Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study.

Authors:  Amy B Hont; C Russell Cruz; Robert Ulrey; Barbara O'Brien; Maja Stanojevic; Anushree Datar; Shuroug Albihani; Devin Saunders; Ryo Hanajiri; Karuna Panchapakesan; Sam Darko; Payal Banerjee; Maria Fernanda Fortiz; Fahmida Hoq; Haili Lang; Yunfei Wang; Patrick J Hanley; Jeffrey S Dome; Catherine M Bollard; Holly J Meany
Journal:  J Clin Oncol       Date:  2019-07-29       Impact factor: 44.544

3.  Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.

Authors:  Stine H Kresse; Halfdan Rydbeck; Magne Skårn; Heidi M Namløs; Ana H Barragan-Polania; Anne-Marie Cleton-Jansen; Massimo Serra; Knut Liestøl; Pancras C W Hogendoorn; Eivind Hovig; Ola Myklebost; Leonardo A Meza-Zepeda
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

4.  Immunotherapy targets in pediatric cancer.

Authors:  Rimas J Orentas; Daniel W Lee; Crystal Mackall
Journal:  Front Oncol       Date:  2012-01-30       Impact factor: 6.244

5.  HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME).

Authors:  Marco Grillini; Costantino Ricci; Vincenzo Pino; Silvia Pedrini; Michelangelo Fiorentino; Barbara Corti
Journal:  Appl Immunohistochem Mol Morphol       Date:  2022-01-01

6.  Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies.

Authors:  Maja Stanojevic; Amy B Hont; Ashley Geiger; Samuel O'Brien; Robert Ulrey; Melanie Grant; Anushree Datar; Ping-Hsien Lee; Haili Lang; Conrad R Y Cruz; Patrick J Hanley; A John Barrett; Michael D Keller; Catherine M Bollard
Journal:  Cytotherapy       Date:  2021-04-05       Impact factor: 6.196

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.